Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical corticosteroids and insulin sensitivity / bone turnover in atopic dermatitis
2018-004370-96Phase 4Completed
- Sponsor
- Jacob Pontoppidan Thyssen
- Start
- Dec 2018
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial in atopic dermatitis (AD) comparing Betnovate arm with Tacrolimus arm (2 arms). Primary endpoint: Whole-body insulin sensitivity (primary). Started Dec 2018; status: completed.
02
Drugs
betamethasonetacrolimus
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on 2018-004370-96.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004370-96.